ArticleMethods in molecular biology (Clifton, N.J.)2025
Utility of Induced Pluripotent Stem Cell-Based Microphysiological Systems for Drug Development and Testing.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microphysiological systems (MPS), i.e., miniaturized mimics of active biological systems, are considered resourceful tools for facilitating drug development. It presupposes that a microphysiological system can respond as organs and tissues in the human body to new drug candidates and that relevant cellular response can be monitored. If, or when, this is possible, microphysiological systems have the potential to support and accelerate the development and testing of new drug candidates.So far, the focus has been more on the design and fabrication of the microarchitecture of the MPS to recreate their cellular counterparts as closely and realistically as possible. Commercial MPS devices have been developed that focus on advanced technological design solutions, sometimes more than their actual biological functionality.This chapter discusses in brief terms the prerequisites for the design and construction of MPS devices in relation to their utility for drug development and testing in a more holistic manner. The use of induced pluripotent cells as a prime source for mimicking the in vivo conditions of diseased conditions is mainly considered. Existing limitations and needs are highlighted in relation to the space for improvements, based on recently published results.
Indexed as
Identifiers
40307642What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.